Table 3 Associations of CNV with clinico-pathologic UCB characteristics in 43 UCB patients treated with RC.

Parameters	Clinical tumor stage	Clinical tumor grade		Urothelial carcinoma histology	Combined tumor stage	Combined disease stage		Pathologic tumor stage	Lymph node status	Number of lymph nodes removed	LVI	MVI		STSM		Presence of incidental prostate cancer		Recurrence	Survival
Source	Serum	Serum	Met	Tumor	Tumor	Tumor	Met	Tumor	Met	Tumor	Tumor	Tumor	Serum	Tumor	Serum	Tumor	Serum	Tumor	Tumor
Genes_Exon
MET_4		n.a.
MET_10		n.a.
MET_21		0.003
GATA4_1	0.016											0.334		0.518
GATA4_3	n.a.											0.014		0.628
GATA4_7	n.a.											0.683		0.039
FGFR1_13				0.487
FGFR1_5				0.223
FGFR1_2				0.014
MYC_1	0.016									0.013		0.803
MYC_2	0.172									0.521		0.045
MYC_3	0.172									0.977		0.133
MYC_1,2,3								0.038
PTP4A3_3	0.001		n.a.					0.005							0.035
PTP4A3_5	n.a		0.005					0.075							0.035
CCND1_2										0.045			0.465				0.018
CCND1_4										0.035			0.004				0.317
CCND1_5										0.035			0.004				0.317
CCND1_2,4,5										0.025
KRAS_6	0.0001														0.035
KRAS_4	0.285														0.740
KRAS_3	n.a.														n.a
KLF5_2			n.a					0.005				0.683
KLF5_3			0.071					0.445				0.783
KLF5_4			0.005					0.475				0.014
ERBB2_13			0.001	0.027	0.018	0.030		0.027			0.062	0.065			0.243	0.005		0.008
ERBB2_23			0.001	0.024	0.275	0.075		0.547			0.012	0.019			0.035	0.029		0.086
ERBB2_30			0.001	0.004	0.048	0.059		0.078			0.048	0.0001			0.243	0.255		0.006
ERBB2_13,23,30																		0.006
TOP2A_20			0.0001											0.039	n.a.			0.002
TOP2A_14			0.005											0.039	0.035			0.002
CCNE1_5																0.029
CCNE1_10																0.029
CCNE1_12																0.029
CCNE1_5,10,12																0.029
n Exons			0.037				0.019		0.019							0.003		0.303	0.333
n Genes			0.009				0.087		0.087							0.015		0.043	0.032

Only those genes with CNV are shown. The significant p-values are in bold. The insignificant p-values are also shown if one or two exons of the same gene display a significant p-value.
EGFR epidermal growth factor receptor, MET mesenchymal-epithelial transition, GATA4 GATA binding protein 4, FGFR1 fibroblast growth factor receptor 1, MYC myelocytomatosis, PTP4A3 protein tyrosine phosphatase 4A3, CCND1 cyclin D1, KLF5 Kruppel-like Factor 5, ERBB2 Erb-b2 receptor tyrosine kinase 2, TOP2A DNA topoisomerase II alpha, CCNE1 cyclin E1, TURB transurethral resection of bladder, RCE radical cystectomy, ConcCIS concomitant carcinoma in situ, N lymph node, MVI microvessel invasion, STSM soft tissue surgical margin, PCa prostate cancer, n number.

Search